Chronic kidney disease (CKD) is a growing global health concern associated with a high risk of cardiovascular disease (CVD) and mortality. Dyslipidaemia is a common metabolic abnormality in CKD, characterised by elevated triglycerides, reduced high-density lipoprotein (HDL), increased small dense low-density lipoprotein (LDL), and elevated lipoprotein(a) levels. These lipid abnormalities contribute significantly to the development of atherosclerosis, inflammation, and oxidative stress, thereby accelerating cardiovascular complications in CKD patients. The pathogenesis involves impaired lipid metabolism, reduced lipoprotein clearance, altered enzyme activity, and changes in lipoprotein composition and function. Additionally, CKD alters the structure and function of HDL and LDL particles, increasing their atherogenic potential. Management strategies primarily include lipid-lowering therapies such as statins and fibrates, along with lifestyle modifications. However, the effectiveness of these treatments may vary depending on the stage of CKD. Early identification and appropriate management of dyslipidaemia are essential to reduce cardiovascular risk and improve clinical outcomes in CKD patients.
Aswini Priya B.1*, Soumya R. V.2, Dr. Vismaya V. R.3, Anila N.1, Roshin Robert1, Atmaj S.1, Dr. Nithin Manohar4, Dr. Prasobh G. R.5 (Mon,) studied this question.